25 Total results for product and free and sample content found
14 Apr 2022
Our world was disrupted at warp speed during 2020. Are you ready to gain a deeper understanding of the year that changed our perceptions of possible?
By Stephanie Yip 23 Oct 2020
In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.
09 Oct 2020
Gain Clarity of Sight into What Comes Next with Citeline According to Informa’s Pharmaprojects, less than 3% of all rare congenital and genetic diseases have an approved therapy. Opportunities abound if you know the risks. Make better strategic and planning decisions with Intelligence services that give you a clear line of sight, helping you maximize clinical and commercial opportunities, navigate uncertainties, and ensure more successful outcomes.
16 Aug 2019
Datamonitor Healthcare recently surveyed 60 gastroenterologists in the US and five major EU markets after the approval of the first disease-specific therapies for the treatment of non-alcoholic steatohepatitis (NASH). The market for these treatments will exceed $21bn in 2027.
By Melanie Senior 08 Aug 2019
Scientists now understand that there are multiple, bi-directional links between gut and brain. They are using this knowledge to develop new treatments for some of the most challenging chronic conditions, including Alzheimer’s disease, Parkinson’s disease and obesity.
02 Jul 2019
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
11 Jun 2019
PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
30 May 2019
Pharma R&D Annual Review 2019 is based on the stats and data from from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects.
By Niharika Dandamudi 15 Apr 2019
Lysosomal storage diseases (LSDs) are a rare distinct group of disorders with complex diagnosis and limited epidemiology data, such as Pompe disease. In recognition of International Pompe Day, marked on April 15, we created the below infographic to provide some insight into epidemiology and present an overview of current treatment options.
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: